Combination of Everolimus and Tacrolimus in Kidney Transplant Patients With Intolerance to Mycophenolate Mofetil/Mycophenolic Acid

Balda, Sagrario; Inza, A.; Odriozola, N.; Zárraga, Sofía; García-Erauskin, G.; Lampreabe, I

doi:10.1016/j.transproceed.2009.06.061

Cited by 1 publication

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…276 In the setting of MPA intolerance, use of mTORi has been reported as an effective alternative following kidney transplantation. 311,312 Care of pancreas transplant recipients is often complicated by gastroparesis that may be exacerbated by MPA-based M-IMS regimen. Consequently, use of mTORi as a rescue therapy in setting of MPA-associated GI intolerance has been extensively explored.…”

Section: Recommendation 10 Evidence Summary: Role Of Mtori In Kidney ...mentioning

confidence: 99%

See 1 more Smart Citation

Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation

et al. 2022

View full text Add to dashboard Cite

Advances in maintenance immunosuppression over the past three decades have improved solid organ transplantation outcomes dramatically. Uninterrupted access to immunosuppression is paramount to minimize rejection and maintain allograft and patient survival. There is no standardized approach to maintenance immunosuppression management. Agents used vary based on transplanted organ, center‐specific protocol, provider expertise, insurance formularies, ability to cover co‐pays, recipient characteristics and tolerability. Published data reflects this heterogeneity. Despite this limitation, maintenance immunosuppression usage cross pollinates between organ groups with standard of care agents often being used off‐label, making medication access a challenge for many transplant recipients. A multidisciplinary panel of American transplant clinicians was formed to review published literature on maintenance immunosuppression with the goal to formulate consensus recommendations for their use in specific organ groups. These consensus recommendations are intended to provide transplant clinicians with a summary of literature on maintenance immunosuppression in the modern era and to support transplant team members working to secure medication access for patients.

show abstract

Section: Recommendation 10 Evidence Summary: Role Of Mtori In Kidney ...mentioning

confidence: 99%

“…Additionally, one found a significantly reduced risk of antibody‐mediated rejection (AMR) with everolimus in combination with CyA‐ME and prednisone compared to MMF 276 . In the setting of MPA intolerance, use of mTORi has been reported as an effective alternative following kidney transplantation 311,312 …”

Section: Clinical Questions and Recommendationsmentioning

confidence: 99%